|
Market Closed -
London S.E.
12:35:09 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 82.50 GBX | 0.00% |
|
0.00% | +2.48% |
| 10-15 | Arecor Therapeutics Obtains Patents in Europe, US, India, for Rapid-acting Insulin | MT |
| 10-15 | Arecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 Product | CI |
| Market Cap | 37.37M 49.75M 44.63M 41.27M 69.82M 4.74B 70.67M 493M 197M 2.48B 187M 183M 7.87B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 31.81M 42.34M 37.98M 35.12M 59.42M 4.03B 60.14M 420M 167M 2.11B 159M 156M 6.7B | EV / Sales 2026 * |
106x | EV / Sales 2027 * | 181x |
| Free-Float |
55.19% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AREC | Delayed | |
Deutsche Boerse AG
| 6UI | Delayed | |
|
Börse Stuttgart
| 6UI | Delayed |
Last Transcript: Arecor Therapeutics plc
| Current month | +13.79% | ||
| 1 month | -6.78% | ||
| 3 months | +29.92% | ||
| 6 months | +25.00% | ||
| Current year | +2.48% |
| 1 week | 81.25 |  | 85 |
| 1 month | 70 | | 86 |
| Current year | 55.27 | | 95 |
| 1 year | 55.27 | | 95 |
| 3 years | 35.4 | | 199 |
| 5 years | 35.4 | | 449 |
| 10 years | 35.4 | | 472 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 51 | 2021-04-12 |
David J. Ellam
DFI | Director of Finance/CFO | - | 2024-11-17 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 2007-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
BRD | Director/Board Member | 51 | 2021-04-12 |
Mohammad Fazeli
BRD | Director/Board Member | 61 | 2017-08-31 |
Andrew Richards
CHM | Chairman | 66 | 2021-04-12 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/20/26 | Free | Chief Executive Officer | 160,000 | 0.4238% | ||
| 5/20/26 | Free | Executive/Senior Manager | 95,000 | 0.2516% | ||
| 5/20/26 | Free | Chief Financial Officer | 105,000 | 0.2781% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | +15.38% | -56.58% | 49.73M | |
| +0.65% | -3.36% | +36.98% | +60.50% | 63.48B | |
| +1.76% | +1.27% | +11.82% | +81.21% | 54.55B | |
| -0.94% | +0.99% | +10.45% | +100.19% | 53.59B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 44.75B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 41.62B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 39.91B | |
| +0.64% | -3.95% | +11.15% | +45.57% | 32.47B | |
| +29.06% | +47.63% | +107.12% | +92.73% | 26.7B | |
| -2.94% | -0.62% | +22.96% | -10.93% | 23.36B | |
| Average | +3.44% | +0.05% | +48.61% | +140.09% | 38.05B | |
| Weighted average by Cap. | +2.83% | +0.19% | +47.99% | +160.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 300K 399K 358K 331K 560K 38.03M 567K 3.96M 1.58M 19.9M 1.5M 1.47M 63.18M | 205K 273K 245K 226K 383K 25.99M 388K 2.71M 1.08M 13.6M 1.02M 1M 43.17M |
| Net income | - | - |
| Net Debt | -5.57M -7.41M -6.65M -6.15M -10.4M -706M -10.53M -73.5M -29.27M -369M -27.81M -27.22M -1.17B | -249K -331K -297K -275K -465K -31.54M -470K -3.28M -1.31M -16.51M -1.24M -1.22M -52.4M |
Employees
33
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | GBX 82.50 | 0.00% | 22,423 |
| 26-10-27 | GBX 82.50 | 0.00% | 54 |
| 26-10-26 | GBX 82.50 | 0.00% | 0 |
| 26-10-23 | GBX 82.50 | 0.00% | 1,466 |
| 26-10-22 | GBX 82.50 | 0.00% | 1,810 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8250GBP
Average target price
2.505GBP
Spread / Average Target
+203.64%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AREC Stock
Select your edition
All financial news and data tailored to specific country editions
